Onesource Specialty Pharma Ltd. (ONESOURCE) — Tipsheet https://tipsheet.markets/company/onesource/ Every Tipsheet Editorial note covering Onesource Specialty Pharma Ltd. (ONESOURCE), newest first. Grounded in BSE/NSE primary-source filings. en-in Mon, 06 Jul 2026 10:22:48 GMT OneSource gets single FDA observation, PAT collapse looms larger https://tipsheet.markets/onesource-onesource-gets-single-fda-observation-pat-collapse-looms-larger-118371/ https://tipsheet.markets/onesource-onesource-gets-single-fda-observation-pat-collapse-looms-larger-118371/ Thu, 02 Jul 2026 15:05:51 GMT A routine US FDA inspection at its Bengaluru sterile facility ended with one observation. A benign outcome, but with profit after tax down 95.3%, the agency finding is not the main worry. A routine US FDA inspection at its Bengaluru sterile facility ended with one observation. A benign outcome, but with profit after tax down 95.3%, the agency finding is not the main worry.

What’s new

  • Routine US FDA cGMP inspection at Sterile Product Division concluded with one observation.
  • Company will respond within stipulated timeframe; no warning letter or import alert issued.
  • Inspection ran June 22-30, 2026; outcome is a single Form 483 observation.

Why it matters

A single observation at a mid-cap CDMO is typically a non-event, suggesting good compliance. But OneSource's PAT has slumped 95.3% on flat revenue. The FDA finding removes a regulatory overhang for now, but the earnings narrative is the real open question.

What we’re watching

  • Nature of the observation, which remains undisclosed.
  • Company's formal response and any follow-up from FDA.
  • Next quarterly results: can revenue accelerate to reverse the PAT collapse?

The full read

OneSource Specialty Pharma came out of a routine US FDA cGMP inspection at its Bengaluru sterile facility with just one observation. No warning letter. No import alert. For a mid-cap CDMO, that is about as clean a result as a routine inspection produces. The company says it will respond in time. That is the short version. The longer version is that OneSource's profit after tax has collapsed 95.3% on near-flat revenue of just 0.5% growth. A clean FDA report lifts a regulatory cloud, but it does not fix the earnings story. The ₹17,646 cr company carries virtually no debt (D/E 0.13), so the balance sheet is not the worry. The open question is whether revenue can accelerate enough to reverse the profit slide. The FDA outcome buys time, not answers.

Primary source: BSE · NSE

]]> Other Tipsheet Editorial